SAFETY AND PHARMACOKINETICS OF A PRESERVATIVE-FREE TRIAMCINOLONE ACETONIDE FORMULATION FOR INTRAVITREAL ADMINISTRATION

Abstract

The half-life of TA in the vitreous after a 4-mg injection of either TA-PF or Kenalog was comparable. A 16-mg dose of TA-PF produced a long vitreous half-life, and this may be of clinical benefit in patients requiring 6 months of drug exposure in the eye for a chronic disease.